Ocugen's December Proxy Fight Exposes the Fault Line Beneath Its 2027 Data Horizon

Ocugen shareholders have just been handed a second waiting game. The ballot on a proposal to raise the company's authorized common stock by 250,000,000 shares has been pushed back to December 22, 2026, with a fresh record date of October 30, 2026. Management needed more time to round up the votes — a delay that speaks louder about investor resistance than any proxy filing could.

The postponement lands on top of a far longer countdown. Topline results from the Phase 3 liMeliGhT study are not expected until the first quarter of 2027, leaving a yawning gap between the company's commercial ambitions and the clinical proof that would underwrite them.

A MENA Licence With Big Numbers and a Long Fuse

Ocugen's most concrete step of late is an exclusive licensing agreement with Roots Pharmaceutical Company WLL and its strategic partner Al-Dhow International Holding, covering the gene therapy OCU400 for retinitis pigmentosa across the Middle East and North Africa. The terms carry real headline weight: an upfront payment, development milestones of up to $4 million, sales-linked milestones of up to $255 million, and royalties of 22% on net sales. Ocugen retains responsibility for manufacturing and supply.

Yet the economics only switch on once the efficacy data land. Until then, the contracted revenue streams are paper promises, however large the zeros on them. The deal does show that the technology carries assignable value and that the company is building distribution channels outside its home market well ahead of approval — but it does nothing to shorten the wait.

Europe, Insiders and a Share Count That Won't Sit Still

Ocugen has also been laying institutional groundwork abroad, appointing Jolanda Crombach as managing director of its European subsidiary in Amsterdam. Alongside that expansion, signals from the top of the company have been less reassuring. CEO Shankar Musunuri sold 468,727 Ocugen shares on October 9, while KVM Holdings, LLC disposed of stock indirectly. Both transactions ran through a pre-arranged Rule 10b5-1 trading plan, which blunts the timing question but not the psychology: insider selling in an already fragile phase rarely reads well to the market.

Then there is the dilution overhang. A share authorization of that magnitude, if approved, would weigh heavily on existing holders — and the fact that management is still hunting for votes suggests broad backing is not yet there.

The Tape Tells Its Own Story

The stock closed Friday at 0.7110 euros, barely above its 52-week low of 0.7050 euros, and has shed 43% since the start of the year. The picture is one of a market that has priced in patience and then some.

What investors are left with is a pipeline of genuine potential, a set of alliances that validate the science commercially, and a calendar whose decisive entries sit years away. Between now and the first quarter of 2027, the burden falls on the balance sheet — and on management's ability to convince shareholders that a larger share count is a bridge to the data, not a dilution of their claim on it.